皇家华人

header-logo
Main Campus Entrance-MKE
Neurosurgery

Budde Lab

Dr. Matthew Budde

The mission of our collaborative research group is to improve care and outcomes for patients with injury and diseases affecting the spinal cord. Our contribution to this goal has focused on developing and employing magnetic resonance imaging (MRI) as a tool to understand spinal cord biology and pathology. MRI is routinely used in the clinical setting for diagnosis and prognosis, and we have used its translational value to bridge the gap between preclinical animal studies and human clinical research.

We have principally focused on two techniques: diffusion and perfusion MRI. Diffusion MRI can be used to detect microscopic damage that is often invisible or difficult to interpret using conventional MRI scans. Using a variety of other experimental methods such as animal studies, histology, and computational simulations helped us develop new diffusion MRI methods to very clearly reveal microscopic damage to the spinal cord. We have recently translated these advances to studies of acute SCI trauma patients. A complementary technique, perfusion MRI, is able to measure blood flow in the spinal cord. Although cord perfusion is believed to be critical to recovery, the technologies available to detect and measure spinal cord perfusion have not been reliable and, therefore, it has not been used routinely. We developed perfusion MRI in preclinical experiments to clearly detect the extent of blood flow deficits and are also actively working to translate the same technology to patients. Collectively, we believe our research will contribute to the discovery of better treatment options available to patients and are grateful to our sources of funding: National Institutes of Health, Department of Veteran鈥檚 Affairs, Craig H. Neilsen Foundation, Department of Defense, and MCW Center for Imaging Research.

Ongoing Studies

all
Noninvasive Spinal Cord Perfusion Techniques with MRI
This project seeks to develop techniques to monitor perfusion of the spinal cord noninvasively with MRI. Blood flow and perfusion of the injured spinal cord is believed to be an important feature for diagnosis and management of the acutely injured cord, but the ability to detect in patients is limited. This study will first develop and optimize MRI methods for spinal cord perfusion in a preclinical model and relate the detected features with axonal injury and neurologic outcomes. The overarching goal is to improve the care and outcomes in patients with SCI.
Funding: National Institutes of Health
 
Monitoring Early Acute Therapeutic Responses with MRI in Preclinical Spinal Cord Injury
The goal of this study and its value to spinal cord injury research is to establish a rigorous and clinically-relevant translational paradigm with integrated biomarkers into preclinical therapy testing.  We will examine whether acute MRI markers of injury, including diffusion and perfusion MRI, are capable of detecting the effects of proven pharmacologic and surgical therapies in a preclinical model.  The overarching goal is to provide clinical management teams and clinical trials with markers to gauge the efficacy of interventions.
Funding: Department of Defense
Advanced MRI of the Injured Human Spinal Cord
This project will utilize advanced MRI markers of spinal cord damage in patients with acute human spinal cord injury with the goal of predicting neurological outcome. SCI is a heterogeneous injury and our prior work in preclinical models demonstrated a specialized type of diffusion MRI that has high sensitivity to axonal injury, the pathological features most associated with neurological dysfunction. The goal of this project is to identify improved diagnostic imaging markers of spinal cord injury and outcomes to improve patient care and refine clinical trials.
Funding: Craig H. Neilsen Foundation and the Department of Veteran’s Affairs.

Recent Publications

  • (Santini T, Shim A, Liou JJ, Rahman N, Varela-Mattatall G, Budde MD, Inoue W, Everling S, Baron CA.) Magn Reson Med. 2025 Feb;93(2):788-802 PMID: 39323069 PMCID: PMC11604852 SCOPUS ID: 2-s2.0-85205058687 09/26/2024

  • (Everson CA, Szabo A, Plyer C, Hammeke TA, Stemper BD, Budde MD.) Exp Neurol. 2024 Nov;381:114928 PMID: 39168169 SCOPUS ID: 2-s2.0-85201764724 08/22/2024

  • (Koch KM, Nencka AS, Kurpad S, Budde MD.) J Neurotrauma. 2024 Sep;41(17-18):2125-2132 PMID: 38251658 SCOPUS ID: 2-s2.0-85190264996 01/22/2024

  • (Lee S, Schmit BD, Kurpad SN, Budde MD.) NMR Biomed. 2024 Jun;37(6):e5115 PMID: 38355219 PMCID: PMC11078600 SCOPUS ID: 2-s2.0-85185526294 02/15/2024

  • (Labounek R, Bondy MT, Paulson AL, Bédard S, Abramovic M, Alonso-Ortiz E, Atcheson NT, Barlow LR, Barry RL, Barth M, Battiston M, Büchel C, Budde MD, Callot V, Combes A, De Leener B, Descoteaux M, de Sousa PL, Dostál M, Doyon J, Dvorak AV, Eippert F, Epperson KR, Epperson KS, Freund P, Finsterbusch J, Foias A, Fratini M, Fukunaga I, Gandini Wheeler-Kingshott CAM, Germani G, Gilbert G, Giove F, Grussu F, Hagiwara A, Henry PG, Horák T, Hori M, Joers JM, Kamiya K, Karbasforoushan H, Ke艡kovský M, Khatibi A, Kim JW, Kinany N, Kitzler H, Kolind S, Kong Y, Kudli膷ka P, Kuntke P, Kurniawan ND, Kusmia S, Laganà MM, Laule C, Law CSW, Leutritz T, Liu Y, Llufriu S, Mackey S, Martin AR, Martinez-Heras E, Mattera L, O'Grady KP, Papinutto N, Papp D, Pareto D, Parrish TB, Pichiecchio A, Prados F, Rovira À, Ruitenberg MJ, Samson RS, Savini G, Seif M, Seifert AC, Smith AK, Smith SA, Smith ZA, Solana E, Suzuki Y, Tackley GW, Tinnermann A, Valo拧ek J, Van De Ville D, Yiannakas MC, Weber KA 2nd, Weiskopf N, Wise RG, Wyss PO, Xu J, Cohen-Adad J, Lenglet C, Nestra拧il I.) bioRxiv. 2024 May 01 PMID: 38746371 PMCID: PMC11092490 05/15/2024

  • (Zhou M, Stobbe R, Szczepankiewicz F, Budde M, Buck B, Kate M, Lloret M, Fairall P, Butcher K, Shuaib A, Emery D, Nilsson M, Westin CF, Beaulieu C.) Magn Reson Med. 2024 May;91(5):2126-2141 PMID: 38156813 SCOPUS ID: 2-s2.0-85181197209 01/02/2024

  • (Everson CA, Szabo A, Plyer C, Hammeke TA, Stemper BD, Budde MD.) Exp Neurol. 2024 Feb;372:114620 PMID: 38029810 SCOPUS ID: 2-s2.0-85179070318 11/30/2023

  • (Zhou M, Stobbe R, Szczepankiewicz F, Budde M, Buck B, Kate M, Lloret M, Fairall P, Butcher K, Shuaib A, Emery D, Nilsson M, Westin CF, Beaulieu C.) Magnetic Resonance in Medicine. May 2024;91(5):2126-2141 SCOPUS ID: 2-s2.0-85181197209 05/01/2024

  • (Singhal I, Harinathan B, Warraich A, Purushothaman Y, Budde MD, Yoganandan N, Vedantam A.) N Am Spine Soc J. 2023 Sep;15:100246 PMID: 37636342 PMCID: PMC10448221 08/28/2023

  • (Ahmed RU, Medina-Aguinaga D, Adams S, Knibbe CA, Morgan M, Gibson D, Kim JW, Sharma M, Chopra M, Davison S, Sherwood LC, Negahdar MJ, Bert R, Ugiliweneza B, Hubscher C, Budde MD, Xu J, Boakye M.) Ann Clin Transl Neurol. 2023 Sep;10(9):1647-1661 PMID: 37501362 PMCID: PMC10502634 SCOPUS ID: 2-s2.0-85165898607 07/28/2023

  • (Vedantam A, Harinathan B, Purushothaman Y, Scripp S, Banerjee A, Warraich A, Budde MD, Yoganandan N.) Biomechanics and Modeling in Mechanobiology. December 2023;22(6):1789-1799 SCOPUS ID: 2-s2.0-85161620932 12/01/2023

  • (Ahmed RU, Medina-Aguinaga D, Adams S, Knibbe CA, Morgan M, Gibson D, Kim Jw, Sharma M, Chopra M, Davison S, Sherwood LC, Negahdar MJ, Bert R, Ugiliweneza B, Hubscher C, Budde MD, Xu J, Boakye M.) Annals of Clinical and Translational Neurology. September 2023;10(9):1647-1661 SCOPUS ID: 2-s2.0-85165898607 09/01/2023

Publications of from the

© 2024 皇家华人.  All rights reserved.  | Terms and Privacy 

Non-Discrimination Statement
The 皇家华人 (MCW) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, or military status. Employees, students, applicants or other members of the MCW community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic. MCW’s policy as well as federal and state laws and regulations prohibit unlawful discrimination and harassment.